The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
Negrier
C
C
Haemophilia Comprehensive Care Center, Edouard Herriot University Hospital, Lyon, France. claude.negrier@chu-lyon.fr
D004305:Dose-Response Relationship, Drug; D005167:Factor VII / Q000008:administration & dosage* / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000627:therapeutic use
D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa